Oh I think HB agrees. There is a reason the company has not invested one dime in any more reg trials for Pona (even though they can, as they have said many times the is no FDA reason not to). GIST going nowhere. Camidge at ASH not mentioning Pona as a lung drug (v'a'v' the video he made). Essential no new R&D spend on Pona beyond the FDA directed current label/dosing trial (which serves only the current label).
I think there is a good chance that all that is left for Pona beyond CML salvage is off-label. And that Alzheimer's dream is finished, too. HB said so.
mN needs to be a winner, and '113 really needs to shine earlier than expected. As it stands, Pona is a salvage drug, and as Pona goes, goes Ariad.
Did Ariad discuss the AP SEs or do they not matter because the life expectancy is too short in AP patients?
News 
Market Data 
Discover 
